Vorinostat 100 MG Oral Capsule Zolinza

1 INDICATIONS AND USAGE ZOLINZA ® is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. ZOLINZA is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies. ( 1 )

Merck Sharp & Dohme Corp.

FDA Reported Adverse Reactions
`[1] dyspnoea` `[2] drug ineffective` `[3] fatigue` `[4] nausea` `[5] wrong technique in product usage process` `[6] diarrhoea` `[7] no adverse event` `[8] off label use` `[9] headache` `[10] chronic kidney disease`

4 years ago

CAPSULE WHITE 568 100 mg

16 HOW SUPPLIED/STORAGE AND HANDLING ZOLINZA capsules, 100 mg, are white, opaque hard gelatin capsules with "568" over "100 mg" printed within the radial bar in black ink on the capsule body. They are supplied as follows: NDC 0006-0568-40. Each bottle contains 120 capsules. Storage and Handling Store at 20-25°C (68-77°F), excursions permitted between 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published. 1 There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate. ZOLINZA (

VORINOSTAT) capsules should not be opened or crushed. Direct contact of the powder in ZOLINZA capsules with the skin or mucous membranes should be avoided. If such contact occurs, wash thoroughly as outlined in the references. Personnel should avoid exposure to crushed and/or broken capsules [see Nonclinical Toxicology (13.1) ].

More pills like CAPSULE 568 100 mg

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site

Vorinostat 100 MG Oral Capsule Zolinza

FDA Reported Adverse Reactions [1] dyspnoea [2] drug ineffective [3] fatigue [4] nausea [5] wrong technique in product usage process [6] diarrhoea [7] no adverse event [8] off label use [9] headache [10] chronic kidney disease

CAPSULE WHITE 568 100 mg

More pills like CAPSULE 568 100 mg

FDA Reported Adverse Reactions
`[1] dyspnoea` `[2] drug ineffective` `[3] fatigue` `[4] nausea` `[5] wrong technique in product usage process` `[6] diarrhoea` `[7] no adverse event` `[8] off label use` `[9] headache` `[10] chronic kidney disease`